Spruce Biosciences, Inc.
TA-ERT
MPS IIIB
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on TA-ERT for MPS IIIB is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“confirmatory study in patients with MPS IIIB and expanded access program to support continued patient access prior to and following potential approval.”